Elke Lipka
Principal investigator.
Medtech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2014First federal award
$27.9MFederal grants as PI31 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
31 awards · $27.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 9, 2026 | NIH | SBIR Phase II Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease | $1.1M | TSRL, INC. |
| Sep 15, 2025 | NIH | SBIR Phase II Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder disease | $1.1M | TSRL, INC. |
| Sep 3, 2025 | NIH | SBIR Phase II Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | $1000K | TSRL, INC. |
| Mar 4, 2025 | NIH | SBIR Phase II Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections. | $1000K | TSRL, INC. |
| Aug 16, 2024 | NIH | SBIR Phase II Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | $1000K | TSRL, INC. |
| Apr 24, 2024 | NIH | SBIR Phase II Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | $999K | TSRL, INC. |
| Mar 4, 2024 | NIH | SBIR Phase II Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections. | $998K | TSRL, INC. |
| Aug 1, 2023 | NIH | SBIR Phase I Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu | $300K | TSRL, INC. |
| Apr 25, 2023 | NIH | SBIR Phase II Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections. | $999K | TSRL, INC. |
| Apr 5, 2023 | NIH | SBIR Phase II Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | $1000K | TSRL, INC. |
| Jan 6, 2023 | NIH | SBIR Phase II Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis | $644K | TSRL, INC. |
| Sep 19, 2022 | NIH | SBIR Phase I Microneedle Delivery of Trospium Chloride Optimized for Improved Tolerance and Patient Outcomes in Overactive Bladder Disease | $300K | TSRL, INC. |
| Aug 10, 2022 | NIH | SBIR Phase I Novel, Safe, Efficacious Heparin Reversal | $394K | TSRL, INC. |
| May 1, 2022 | NIH | SBIR Phase II Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections | $2.0M | TSRL, INC. |
| Feb 15, 2022 | NIH | SBIR Phase II Development of Synthetic High-Density Lipoproteins for Treatment of Sepsis | $1.6M | TSRL, INC. |
| Mar 25, 2021 | NIH | SBIR Phase II Microneedle Delivery of Zanamivir for Treatment of Influenza | $952K | TSRL, INC. |
| Mar 25, 2020 | NIH | SBIR Phase II Microneedle Delivery of Zanamivir for Treatment of Influenza | $972K | TSRL, INC. |
| Feb 19, 2020 | NIH | STTR Phase I A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections | $270K | TSRL, INC. |
| Jul 2, 2019 | NIH | SBIR Phase II Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections | $971K | TSRL, INC. |
| Mar 21, 2019 | NIH | SBIR Phase II Microneedle Delivery of Zanamivir for Treatment of Influenza | $999K | TSRL, INC. |
| Mar 6, 2019 | NIH | STTR Phase I A Novel Combination Therapy to Treat Biofilm-based Pneumonia Infections | $300K | TSRL, INC. |
| Jul 17, 2018 | NIH | SBIR Phase II Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections | $984K | TSRL, INC. |
| Jul 13, 2018 | NIH | STTR Phase I Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections | $300K | TSRL, INC. |
| Mar 1, 2018 | NIH | SBIR Phase I Microneedle Delivery of Zanamivir for Treatment of Influenza Infections | $285K | TSRL, INC. |
| Aug 2, 2017 | NIH | SBIR Phase II Development of methionyl-tRNA synthetase inhibitors for Gram positive bacterial infections | $1.0M | TSRL, INC. |
| Aug 1, 2017 | NIH | STTR Phase I Cell-penetrating antimicrobial therapeutics for treatment of complicated skin and soft tissue infections | $584K | TSRL, INC. with PURDUE UNIVERSITY |
| Mar 1, 2017 | NIH | SBIR Phase I Microneedle Delivery of Zanamivir for Treatment of Influenza Infections | $573K | TSRL, INC. |
| Nov 17, 2016 | NIH | SBIR Phase II Broad Spectrum Antiviral Nucleoside Phosphonate Analogs | $1000K | TSRL, INC. |
| Nov 10, 2015 | NIH | SBIR Phase II Broad Spectrum Antiviral Nucleoside Phosphonate Analogs | $990K | TSRL, INC. |
| May 7, 2015 | NIH | SBIR Phase I Nucleoside Phosphonate Analogs for the Treatment of Adenoviral Infection | $299K | TSRL, INC. |
| Dec 16, 2014 | NIH | SBIR Phase II Broad Spectrum Antiviral Nucleoside Phosphonate Analogs | $3.0M | TSRL, INC. |
1 patents as inventor
- US TSRL, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#3
Awards as PI#6
Patents#505
Companies
- TSRL, INC.Linked by awards · Medtech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.